Description: ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Balma, France.
Home Page: abionyx.com
33 43 av. Georges Pompidou Bât. D2
Balma,
31130
France
Phone:
33 5 62 24 97 06
Officers
| Name | Title |
|---|---|
| Sir Cyrille Tupin CPA | CEO, GM & Director |
| Prof. Christian Chavy MBA | Independent Director |
| Mr. Emmanuel De Fougeroux | Administrative & Financial Director |
| Ms. Constance Keyserling Peyrottes M.S. | Vice President of Clinical, Regulatory Development & Operations |
| Dr. Robert Andrew Donald Scott M.D. | Chief Medical Officer and Head of R&D |
| Mr. Laurent Guerci | Chief Digital & Innovation Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.3796 |
| Price-to-Sales TTM: | 8.9349 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 61 |